. Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiol Aging. 2010 Mar;31(3):357-67. Epub 2008 May 19 PubMed.

AlzBiomarker Database

Meta-Analysis

Curated Study Data

Biomarker
(Source)
Cohort
(N)
Measurement
Mean ± SD
Method;
Assay Name;
Manufacturer
Diagnostic
Criteria
Aβ1-40
(Plasma)
MCI-AD
(15)
162 ± 70
pg/mL
xMAP;
INNO-BIA Aβ Forms;
Innogenetics
McKhann et al., 1984
Aβ1-40
(Plasma)
MCI-AD
(48)
208 ± 43
pg/mL
xMAP;
INNO-BIA Aβ Forms;
Innogenetics
McKhann et al., 1984
Aβ1-40
(Plasma)
MCI-Stable
(51)
197 ± 38
pg/mL
xMAP;
INNO-BIA Aβ Forms;
Innogenetics
Petersen, 2004
Aβ1-40
(Plasma)
MCI-Stable
(88)
160 ± 55
pg/mL
xMAP;
INNO-BIA Aβ Forms;
Innogenetics
Petersen, 2004
Aβ1-42
(Plasma)
MCI-AD
(15)
24 ± 10
pg/mL
xMAP;
INNO-BIA Aβ Forms;
Innogenetics
McKhann et al., 1984
Aβ1-42
(Plasma)
MCI-AD
(48)
31 ± 9
pg/mL
xMAP;
INNO-BIA Aβ Forms;
Innogenetics
McKhann et al., 1984
Aβ1-42
(Plasma)
MCI-Stable
(51)
30 ± 9
pg/mL
xMAP;
INNO-BIA Aβ Forms;
Innogenetics
Petersen, 2004
Aβ1-42
(Plasma)
MCI-Stable
(88)
27 ± 8
pg/mL
xMAP;
INNO-BIA Aβ Forms;
Innogenetics
Petersen, 2004

Recommends

Please login to recommend the paper.

Comments

Comments on this Paper

No Available Comments

Make a Comment

To make a comment you must login or register.